科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Vaccines2025-10-07· DNA vaccination

Advances in Pasteurella multocida Vaccine Development: From Conventional to Next-Generation Strategies

Adehanom Baraki Tesfaye, Gebremeskel Mamu Werid, Zhengyu Tao, Liuchao You, Rui Han, Jiayao Zhu, Lei Fu, Yuefeng Chu

原始摘要(英文原文)· Original abstract
Pasteurella multocida is a Gram-negative bacterium causing significant livestock diseases, like fowl cholera and hemorrhagic septicemia in cattle, and wound infection in humans. Classified into four subspecies and five capsular serotypes, it possesses multiple virulence factors, including capsular polysaccharides (CPSs), lipopolysaccharides (LPSs), outer membrane proteins (OMPs), iron acquisition proteins, and toxins that serve as vaccine targets. Antimicrobial treatment is challenging, so vaccination is key. Commercial vaccines include killed and live attenuated types, which are commonly used, though they have intrinsic problems. Advanced vaccines like recombinant subunit and DNA vaccines are emerging. Subunit vaccines targeting OMPs (OmpH, OmpA, PlpE, VacJ, and PmSLP) and recombinant Pasteurella multocida toxin (rPMT) show high efficacy in animal models, and their recombinant proteins induce strong immune responses. DNA vaccines have promise but limited use. The challenges in vaccine development are the strain diversity, short-term immunity, and inconsistent cross-protection. There is also a lack of research on recombinant and subunit vaccine development for small ruminants. Future research should focus on multivalent vaccines, optimization, including improving adjuvants and optimizing DNA vaccine delivery.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Advances in Pasteurella multocida Vaccine Development: From Conventional to Next-Generation Strategies — 科研速览 Science Skim